Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed)
Funding Opportunity PAR-19-104 from the NIH Guide for Grants and Contracts. As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First), the NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First-supported sequencing center. Applicants are encouraged to propose sequencing of existing pediatric cancer cohorts to elucidate the genetic contribution to childhood cancers, or to expand the range of disorders included within the Kids First Data Resource to investigate the genetic etiology of structural birth defects. Whole genome, exome, and transcri...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 14, 2018 Category: Research Source Type: funding
Small Research Grants for Analyses of Data for the Gabriella Miller Kids First Data Resource (R03 - Clinical Trial Not Allowed)
Funding Opportunity PAR-19-069 from the NIH Guide for Grants and Contracts. REISSUE of PAR-18-733 The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotype data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. The overall goal of the Gabriella Miller Kids First Pediatric Data Resource is to help researchers understand the underlying mechanisms of these conditions, leading to more refined diag...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 16, 2018 Category: Research Source Type: funding
NIH Loan Repayment Programs: A Lifeline for Biomedical and Biobehavioral Researchers: Applications Accepted September 1 – November 15
By the time many researchers have completed their education and training, they have amassed on average $160,000 in student loan debt. The NIH Loan Repayment Programs (LRPs) are a set of programs established by Congress and designed to recruit and retain highly qualified health professionals into biomedical or biobehavioral research careers. The LRPs counteract early-career researchers’ financial pressure by repaying up to $35,000 annually ($70,000 over a two-year contract) of a researcher’s qualifying educational debt in return for a commitment to engage in research areas important to the mission of NIH.
Nearly ...
Source: NIH Extramural Nexus - September 28, 2018 Category: Research Authors: Mike Lauer Tags: blog Open Mike Biomedical Workforce loan repayment program LRP Source Type: funding
Limited Competition for the Continuation of the Childhood Liver Disease Research Network (ChiLDReN) Clinical Centers (U01 Clinical Trial Required)
Funding Opportunity RFA-DK-18-501 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to continue the support the Childhood Liver Disease Research Network (ChiLDReN) to conduct clinical and translational research on rare pediatric liver diseases. ChiLDReN is composed of a Scientific and Data Coordination Center (SDCC) and Clinical Centers (CC). ChiLDReN will continue clinical and translational research on pediatric liver diseases that include: Biliary Atresia; Alagille syndrome; alpha-1-antitrypsin deficiency; Progressive Familial Intrahepatic Cholestasis syndromes;...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 18, 2018 Category: Research Source Type: funding
Limited Competition for the Continuation of the Childhood Liver Disease Research Network (ChiLDReN) Scientific and Data Coordinating Center (U24 Clinical Trial Optional)
Funding Opportunity RFA-DK-18-502 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to continue the support the Childhood Liver Disease Research Network (ChiLDReN) to conduct clinical and translational research on rare pediatric liver diseases. ChiLDReN will be composed of a Scientific and Data Coordination Center (DCC), Clinical Centers (CC) , and the NIDDK/NIH as the sponsor of the Network. ChiLDReN will continue clinical and translational research on pediatric liver diseases that include: Biliary Atresia; Alagille syndrome; alpha-1-antitrypsin deficiency; Progr...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 18, 2018 Category: Research Source Type: funding
Limited Competition for the Continuation of the Childhood Liver Disease Research Network (ChiLDReN) Clinical Centers (U01 Clinical Trial Required)
The purpose of this funding opportunity announcement (FOA) is to continue the support the Childhood Liver Disease Research Network (ChiLDReN) to conduct clinical and translational research on rare pediatric liver diseases. ChiLDReN is composed of a Scientific and Data Coordination Center (SDCC) and Clinical Centers (CC). ChiLDReN will continue clinical and translational research on pediatric liver diseases that include: Biliary Atresia; Alagille syndrome; alpha-1-antitrypsin deficiency; Progressive Familial Intrahepatic Cholestasis syndromes; Bile acid synthesis defects; Mitochondrial hepatopathies; Idiopathic Neonatal Hep...
Source: NIDDK Funding Opportunities - September 18, 2018 Category: Endocrinology Source Type: funding
Limited Competition for the Continuation of the Childhood Liver Disease Research Network (ChiLDReN) Scientific and Data Coordinating Center (U24 Clinical Trial Optional)
The purpose of this funding opportunity announcement (FOA) is to continue the support the Childhood Liver Disease Research Network (ChiLDReN) to conduct clinical and translational research on rare pediatric liver diseases. ChiLDReN will be composed of a Scientific and Data Coordination Center (DCC), Clinical Centers (CC) , and the NIDDK/NIH as the sponsor of the Network. ChiLDReN will continue clinical and translational research on pediatric liver diseases that include: Biliary Atresia; Alagille syndrome; alpha-1-antitrypsin deficiency; Progressive Familial Intrahepatic Cholestasis syndromes; Bile acid synthesis defects; M...
Source: NIDDK Funding Opportunities - September 18, 2018 Category: Endocrinology Source Type: funding
Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium (U54 Clinical Trial Not Allowed)
Funding Opportunity RFA-CA-19-016 from the NIH Guide for Grants and Contracts. The FOA will focus on fusion oncoproteins found in tumors that have high risk of treatment failure and for which there has been little progress in identifying targeted agents. Responsive applications can focus on any fusion oncoprotein in pediatric solid tumors or on NUP98 fusion proteins that occur in young children with acute myelogenous leukemia (AML). However, greater preference will be given to applications focused on PAX-FOXO (alveolar rhabdomyosarcoma), C11orf95RELA (ependymoma), or NUP98 fusion proteins. (Source: NIH Funding Opportuni...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 11, 2018 Category: Research Source Type: funding
Limited Competition for NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules (U01) (Clinical Trial Required)
Funding Opportunity PAR-18-910 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications that propose testing new therapeutic uses for experimental drugs or biologics (Assets) across a broad range of human diseases in adult and pediatric populations. This innovative program allows investigators to propose new therapeutic uses for Assets from pharmaceutical company partners. Strong applications will include scientific evidence that modulation of an Assets target will have a positive impact on the disease/condition. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 31, 2018 Category: Research Source Type: funding
Pre-application for the NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules (X02 Clinical Trials Not Allowed)
Funding Opportunity PAR-18-909 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits pre-applications for projects that test new therapeutic uses for experimental drugs or biologics (Assets) across a broad range of human diseases in adult and pediatric populations. This innovative program allows investigators to propose new therapeutic uses for Assets from pharmaceutical company partners. Strong applications will include scientific evidence that modulation of an Assets target will have a positive impact on the disease/condition. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 31, 2018 Category: Research Source Type: funding
Notice of Intent to Publish Funding Opportunity Announcements for the Collaborative Pediatric Critical Care Research Network (CPCCRN) (R01 Clinical Trial Optional)
Notice NOT-HD-18-013 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 31, 2018 Category: Research Source Type: funding
Pediatric Immunotherapy Discovery and Development Network (PI-DDN)(U54 - Clinical Trial Not Allowed)
Funding Opportunity RFA-CA-19-003 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) t...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 13, 2018 Category: Research Source Type: funding
Pediatric Immunotherapy Discovery and Development Network (PI-DDN)(U01 - No Clinical Trial Allowed)
Funding Opportunity RFA-CA-19-004 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The overall goal of this FOA and the companion FOA, RFA-CA-19-012, is to establish a network of collaborating investigators to identify and advance research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 13, 2018 Category: Research Source Type: funding
Molecular Atlas of Lung Development Program (LungMAP) Phase 2 Research Centers (U01- Clinical Trial Not Allowed)
Funding Opportunity RFA-HL-19-020 from the NIH Guide for Grants and Contracts. The National Heart, Lung, and Blood Institute invites cooperative agreement (U01) applications to serve as the Research Center (RC) for the Molecular Atlas of Lung Development Program (LungMAP), Phase 2. The overall objective of LungMAP is to better understand human lung development through building an open-access reference resource of a comprehensive, dynamic, 3-D molecular atlas of the late-stage developing human lung with data and reagents available to the research community. Phase 2 of LungMAP will continue to generate and integrate high-...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 27, 2018 Category: Research Source Type: funding
Molecular Atlas of Lung Development Program (LungMAP) Phase 2 - Human Tissue Core (U01- Clinical Trial Not Allowed)
Funding Opportunity RFA-HL-19-021 from the NIH Guide for Grants and Contracts. The National Heart, Lung, and Blood Institute invites cooperative agreement (U01) applications to serve as the Research Center (RC) for the Molecular Atlas of Lung Development Program (LungMAP), Phase 2. The overall objective of LungMAP is to better understand human lung development through building an open-access reference resource of a comprehensive, dynamic, 3-D molecular atlas of the late-stage developing human lung with data and reagents available to the research community. Phase 2 of LungMAP will continue to generate and integrate high-...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 27, 2018 Category: Research Source Type: funding
